TABLE 2.

List of clinical trials of exosomal drug delivery recorded up to October 2021 (available on https://clinicaltrials.gov/ct2/home).

Clinical trials ID	Status	Study	Conditions	Source	Interventions	Phase
NCT04969172	Active, not recruiting	Overexpressing CD24 to prevent clinical deterioration in patients with moderate or severe COVID-19 infection	COVID-19	Human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24	Exosomes overexpressing CD24 (1010 exosome particles)	Phase II
NCT04902183	Recruiting	Exosomes overexpressing CD24 in two doses for patients with moderate or severe COVID-19	COVID-19	Exosomes overexpressing CD24	CovenD24 (Exo-CD24) 10^9 exosome particles	Phase II
NCT04747574	Recruiting	CD24-Exosomes in patients with COVID-19 infection	SARS-CoV-2	T-REx™-293 cells engineered to express CD24	EXO-CD24 10^8, 10^9, or, 10^10 exosome particles/2 ml	Phase I
NCT03608631	Recruiting	iExosomes in treating participants with metastatic pancreas cancer with KrasG12D mutation	KRAS NP_004976.2:p.G12D metastatic pancreatic adenocarcinoma pancreatic ductal adenocarcinoma stage IV pancreatic cancer AJCC v8	KrasG12D siRNA-loaded MSCs-derived exosomes	MSCs-derived exosomes with KRAS G12D siRNA (dose-escalation study)	Phase I